Financial Performance - The company's revenue for Q3 2023 was ¥604,847,604.65, representing a year-on-year increase of 3.92%[5] - Net profit attributable to shareholders for the same period was ¥43,045,999.77, up 15.57% year-on-year[5] - The net profit excluding non-recurring items reached ¥23,569,354.30, reflecting an 18.58% increase compared to the previous year[5] - The basic earnings per share for Q3 2023 was ¥0.21, a 16.67% increase from the same period last year[5] - Total operating revenue for Q3 2023 reached ¥2,123,962,814.37, an increase of 13.1% compared to ¥1,877,843,111.83 in Q3 2022[20] - Net profit for Q3 2023 was ¥242,376,937.02, representing a 43.3% increase from ¥169,070,013.38 in the same period last year[22] - Earnings per share (EPS) for Q3 2023 was ¥1.16, compared to ¥0.80 in Q3 2022, indicating a significant growth in profitability[22] - The total comprehensive income for Q3 2023 was ¥242,376,937.02, compared to ¥169,070,013.38 in Q3 2022, marking a growth of 43.3%[22] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥6,176,664,110.49, a decrease of 3.65% from the end of the previous year[5] - The company's total liabilities decreased to ¥1,273,181,411.28 from ¥1,377,934,885.05, a reduction of approximately 7.6%[19] - The total equity attributable to shareholders of the parent company was ¥4,889,690,342.90, down from ¥5,020,336,429.41, a decline of 2.6%[19] - As of September 30, 2023, total current assets amount to 3,884,778,176.15 RMB, down from 4,200,735,937.69 RMB at the beginning of the year, representing a decrease of approximately 7.57%[18] - Total assets as of September 30, 2023, are 6,176,664,110.49 RMB, compared to 6,410,837,630.17 RMB at the beginning of the year, indicating a decrease of about 3.64%[18] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥369,874,076.42, showing a significant increase of 639.26%[11] - Operating cash flow for the period reached ¥369,874,076.42, a significant increase from ¥50,032,768.56 in the previous period, reflecting a growth of approximately 638%[23] - Total cash inflow from operating activities was ¥2,378,518,234.09, compared to ¥1,960,786,166.15 in the prior year, indicating a year-over-year increase of about 21%[23] - Cash outflow from operating activities totaled ¥2,008,644,157.67, slightly up from ¥1,910,753,397.59, resulting in a net cash flow from operating activities of ¥369,874,076.42[23] - Cash received from sales of goods and services was ¥2,254,093,718.85, an increase from ¥1,859,304,867.63, marking a growth of approximately 21.2%[23] - The ending cash and cash equivalents balance was ¥1,054,257,326.80, down from ¥1,202,548,446.30, reflecting a decrease of about 12.3% year-over-year[24] Investments and Financing - The company reported a financial income of ¥11,939,341.46, an improvement from a financial expense of ¥21,733,279.91 in the previous year[20] - Investment activities generated a net cash outflow of ¥331,391,837.61, an improvement from a net outflow of ¥712,018,224.01 in the previous year[23] - Cash inflow from financing activities was ¥912,356,517.12, down from ¥1,318,930,716.13, representing a decrease of approximately 31%[24] - The net cash flow from financing activities was -¥354,777,965.82, compared to -¥73,154,862.84 in the same period last year, indicating a worsening cash position[24] - Total cash outflow for investment activities was ¥374,541,545.49, a decrease from ¥945,743,600.10, indicating a reduction in investment spending[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,365[13] - The largest shareholder, Changsha Medical Investment Co., Ltd., holds 40.81% of shares, totaling 85,079,923 shares, with 8,010,000 shares pledged[13] - The company repurchased a total of 3,942,869 shares, accounting for 1.89% of the total share capital, with a total transaction amount of 146,316,517.30 RMB[17] Research and Development - Research and development expenses increased to ¥79,244,096.66, up from ¥70,272,006.27, reflecting a growth of 12.5% year-over-year[20] Other Financial Metrics - The company’s weighted average return on equity increased to 0.88%, up 0.11 percentage points from the previous year[5] - The total non-recurring gains and losses for Q3 2023 amounted to ¥19,476,645.47, with significant contributions from government subsidies and asset disposals[6] - The company has a total of 5,451,696 restricted shares held by executive Zhang Zhimin, which were released from restriction on June 8, 2023[16] - Cash and cash equivalents decreased from 1,449,959,044.04 RMB to 1,175,288,638.27 RMB, a decline of approximately 18.88%[18] - Inventory increased from 529,358,713.74 RMB to 611,860,616.42 RMB, reflecting an increase of about 15.59%[18] - Long-term equity investments decreased slightly from 5,256,052.92 RMB to 5,167,888.95 RMB, a decrease of approximately 1.68%[18] - Fixed assets increased from 1,290,272,314.21 RMB to 1,361,102,756.62 RMB, an increase of about 5.51%[18]
可孚医疗(301087) - 2023 Q3 - 季度财报